Abstract
It has been estimated that well over 5 million prescriptions were written for the anti-obesity drugs in 1966 in the United Kingdom. Since then, the number of scripts issued has steadily fallen to ‘only’ slightly more than 3 million prescriptions in 1975. This figure would suggest that either the anti-obesity drugs are effective or that they are being extensively over-prescribed. At present, more than one-third of subjects enrolling in a slimming organization will have previously taken at least one anti-obesity agent, and more than three-quarters of subjects referred by general practitioners to a hospital obesity clinic will have previously received drug therapy. It follows that subjects with a weight problem of sufficient concern to make them seek medical attention may, at present, reasonably expect to be prescribed a weight-reducing drug. Certainly most general practitioners prescribe at least one anti-obesity agent, and the majority of patients say that they find such drugs are helpful. Indeed, in a recent survey undertaken by the Consumers’ Association, appetite-suppressant drugs were rated by women slimmers to be the best method of achieving rapid weight loss. However, only 16% of these women considered that dieting with the aid of appetite-reducing pills was a successful method of producing a long-term weight loss1.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Consumers Association (1978). Which? Way to Slim. (Portsmouth: Eyre and Spottiswoode Ltd.).
Cornell, P. H. (1975). In M. N. G. Dukes (ed.). Mylers Side Effects of Drugs, vol. 8, p. 1. (Amsterdam-Oxford: Excerpta Medica).
Mackay, R. H. G. (1973). Long-term use of diethylpropion in obesity. Curr. Med. Res. Opinion, 8, 489.
Le Riche, W. H. and Csima, A. (1967). A long acting appetite suppressant drug. Canad. Med. Assoc. J., 97, 1016.
Allen, G. S. (1977). A double blind clinical trial of diethylpropion hydrochloride, mazindol and placebo in the treatment of exogenous obesity. Curr. Ther. Res., 22, 678.
McQuarrie, H. G. D. (1975). Clinical assessment of the use of an anorectic drug in a total weight reduction programme. Curr. Ther. Res., 17, 437.
Bolding, P. T. (1974). Diethylpropion hydrochloride: an effective suppressant. Curr. Ther. Res., 16, 40.
Nolan, G. R. (1975). Use of an anorexic drug in a total weight reduction program in prvate practice. Curr. Ther. Res., 18, 332.
Stewart, D. A., Bailey, J. D. and Patell, H. (1970). Tenuate dospan as an appetite suppressant in the treatment of obese children. App. Therapeut., 12, 34.
Munro, J. F., McCuish, A. C., Wilson, E. M. and Duncan, L. J. P. (1968). Comparison in continuous and intermittent anorectic therapy in obesity. Br. Med. J., 1, 352.
Campbell, C. J., Bhalla, I. P., Steele, H. M. and Duncan, L. J. P. (1977). A controlled trial of phentermine in obese diabetic patients. Practitioner, 218, 851.
Langlois, K. J., Forbes, J. A., Bell, C. W. and Grant, G. F. (Jr). (1974). A double blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (fastin) in the treatment of exogenous obesity. Curr. Ther. Res., 16, 289.
Truant, A. P., Lawrence, P. A. and Cobb, S. (1972). Phentermine resin as an adjunct in medical weight reduction: a controlled randomised double blind prospective study. Curr. Ther. Res., 14, 726.
Moe, J. F. (1977). Phentermine hydrochloride therapy for exogenous obesity: an evaluation of interrupted therapy. Curr. Ther. Res., 22, 666.
Harrison, L. C., King-Roach, A. P. and Sandy, K. C. (1975). Effects of mazindol on carbohydrate and insulin metabolism in obesity. Metabolism, 24(12), 1353.
Wallace, A. G. (1976). An 448 sandoz (mazindol) in the treatment of obesity. Med. J. Aust., 1, 343.
Maclay, W. P. and Wallace, M. G. (1977). A multicentre general practice trial of mazindol in the treatment of obesity. Practitioner, 218.
Clinical trials: comparative merits of two weight reducing drugs (1978). (A report from the General Practice Research Group). J. Pharmacotherapy, 1, 35.
Bradley, M. J., Blum, N. J. and Scheib, R. K. (1974). Mazindol in obesity with known cardiac disease. J. Int. Med. Res., 2, 347.
Bandisode, M. S. and Boshell, B. R. (1975). Double blind clinical evaluation of mazindol (42–558) in obese diabetics. Curr. Ther. Res., 18(6), 816.
Schwartz, L. N. (1975). A non-amphetamine anorectic agent: preclinical background and a double blind clinical trial. J. Int. Med. Res., 3, 328.
Heber, K. R. (1975). Double blind trial of mazindol in overweight patients. Med. J. Aust., 2, 566.
Gomez, G. (1975). Obese patients in general practice: a comparison of the anorectic effects of mazindol, fenfluramine and placebo. Clin. Trials J., 12, 38.
Smith, R. G., Innes, J. A. and Munro, J. F. (1975). Double blind evaluation of mazindol in refractory obesity. Br. Med. J., 3, 284.
Sharma, R. K., Collipp, P. J., Rezvani, I., Strimas, J., Maddaiah, V. T. and Rezvani, E. (1973). Clinical evaluation of the anorexic activity and safety of 42–558 in children. Clin. Pediat., 12, 145.
Allen G. S. (1977). A double blind clinical trial of diethylpropion hydrochloride, mazindol and placebo in the treatment of exogenous obesity. Curr. Ther. Res., 22, 678.
Smith, D. E. (1974). A new anorexiant. Rocky Mountain Med. J., 71(1), 41.
Sedgwick, J. P. (1975). Mazindol in the treatment of obesity. Practitioner, 214, 418.
Conte, A. (1973). Evaluation of sanorex — a new appetite suppressant. Obesity/ Bariatric Med., 2, 104.
Pinder, R. M., Brogden, R. N., Sawyer, P. R., Spreight, P. M. and Avery, G. S. (1975). Fenfluramine: A review of its pharmacological properties and therapeutic efficacy in obesity. Drugs, 10(4), 241.
Innes, J. A., Watson, M. L., Ford, M. J., Munro, J. F., Stoddart, M. E. and Campbell, D. B. (1977). Plasma fenfluramine levels, weight loss and side effects. Br. Med. J., 2, 1322.
Doar, J. W. H., and Thomson, M. E. (1978). The influence of diet and fenfluramine on plasma sugar and insulin levels in patients with newly diagnosed maturity onset diabetes mellitus. Gurr. Med. Res. Opin., (in press).
Stowers, J. M. and Bewsher, P. D. (1969). Studies on the mechanism of weight reduction by phenformin. Postgrad. Med. J. 2, 104.
Cairns, A., Shalet, S., Marshall, A. J. and Hartog, M. (1977). A comparison of phenformin and metformin in the treatment of maturity onset obese diabetes. Diabete et Metabolisme, 3, 183.
Patel, D. P. and Stowers, J. M. (1964). Phenformin in weight reduction of obese diabetics. Lancet, 2, 282.
Clarke, B. F. and Duncan, L. J. P. (1968). Comparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetics. Lancet 1, 123.
Faludi, G., Chayes, Z. and Gerber, P. (1968). Rational treatment of the obese diabetic. Postgrad. Med. J., 43(21), 92.
Lavieuville, M. and Isnard, F. (1975). Retrospective study of the cardiovascular fate of 190 diabetics treated for 5 years or more with biguanides alone. Journees de Diabetologie Hotel-Dieu, p.341.
Mursky, S. and Schwartz, M. (1966). Phenformin diabetic control and body weight. J. Mount Sinai Hosp., 33(2), 180.
Clarke, B. F. and Campbell, I. W. (1977). Comparison of metformin and chlorpropamide in non obese, maturity onset diabetics uncontrolled by diet. Br. Med. J., 2, 1576.
Roginsky, M. S. and Barnett, J. (1966). Double blind study of phenethyl diguanide in weight control of obese nondiabetic subjects. Am. J. Clin. Med., 19(4), 223.
Munro, J. F., MacCuish, A. C., Marshall, A., Wilson, E. M. and Duncan, L. J. P. (1969). Weight reducing effect of biguanides on obese non-diabetic women. Br. Med. J., 2, 13.
Lawson, A. A. H., Strong, J. A., Roscoe, P. and Gibson, A. (1970). Comparisons of fenfluramine and metformin in treatment of obesity. Lancet, 1, 437.
Lutjens, A. and Smit, J. L. J. (1976). Effect of biguanide treatment in obese children. Helv. Paediat. Acta, 31, 473.
Miller, D. S. and Parsonage, S. (1975). Resistance to slimming; adaptation or illusion. Lancet, 1, 773.
Gwinup, G. and Poucher, R. (1967). A controlled study of thyroid analogs in the therapy of obesity. Am. J. Med. Sci., 254, 416.
Bray, G. A. and Greenway, F. L. (1976). Pharmacological approaches to treating the obese patients. In M. J. Albrink (ed.), Clinics in Endocrinology and Metabolism, vol. 54, p.455. (London, Philadephia and Toronto: J. B. Saunders & Co. Ltd).
Kaplan, N. M. and Jose, A. (1970). A controlled study of thyroid analogs in the therapy of obesity. Am. J. Med. Sci., 260, 416.
Hollingsworth, D. R., Amatruda, T. T. (Jr) and Scheig, R. (1970). Quantitative and qualitative effects of L-triiodithyrionine in massive obesity. Metabolism, 19, 934.
Asher, W. L. and Harper, M. W. (1973). Effect of human chorionic gonado-trophin on weight loss, hunger and feeling of well being. Am. J. Clin. Nutr., 26, 211.
Hirsch, J. and Von Itallie, T. B. (1973). The treatment of obesity. Am. J. Clin. Nutr., 26, 1039.
Quaade, F. (1974). Untraditional treatment of obesity. In W. L. Burland, P. A. Samuel and J. Yudkin (eds). Obesity. (Edinburgh, London and New York: Churchill Livingstone).
Thorner, M. O., McNeilly, A. S., Hagan, C. and Besser, G. M. (1974). Long term treatment of galactorrhoea and hypogonadism with bronocriptine. Br. Med. J., 2, 419.
Harrower, A. D. B., Yap, P. L., Nairn, I. M., Walton, H. J., Strong, J. A. and Craig, A. (1977). Growth hormone, insulin and prolactin secretion in anorexia nervosa and obesity during bromocriptine treatment. Br. Med. J., 2, 156.
Quaade, F., Pakkenberg, H. and Juhl, E. (1974). Levo dopa as a treatment of obesity. Acta Med. Scand., 195, 129.
Johanson, A. J. and Knorr, N. J. (1974). Treatment of anorexia nervosa by levo dopa. Lancet, 2, 591.
Scoville, B. A. (1973). Review of amphetamine-like drugs by the Food and Drug Administration. In G. A. Bray (ed.) Obesity in Perspective, p.441. (DHEW Publication No. (NIH) 75-707).
Seaton, D. A., Duncan, L. J. P. and Rose, K. (1961). Diethylproprion in the treatment of ‘refractory’ obesity. Br. Med. J., 1, 1009.
Seaton, D. A., Rose, K. and Duncan, L. J. P. (1964a). A comparison of the appetitite suppressing properties of dexamphetamine and phentermine. Scot. Med. J., 9, 482.
Seaton, D. A., Rose, K. and Duncan, L. J. P. (1964b). Sustained action chlorphentermine in the correction of refractory obesity. Practitioner, 193, 698.
Munro, J. F., Seaton, D. A. and Duncan, L. J. P. (1966). Treatment of refractory obesity with fenfluramine. Br. Med. J., 2, 624.
Silverstone, J. R., Cooper, R. M. and Begg, R. R. (1970). A comparative trial of fenfluramine and diethylpropion in obesity. Br. J. Clin. Pract., 24(10) 624.
Philips, B. L. D. (1977). Treatment of obesity: comparison of diethylpropion and fenfluramine. Clin. Trials. J., 14(2) 1.
Follows, O. J. (1971). A comparative trial of fenfluramine and diethylpropion in obese, hypertensive patients. Br. J. Clin. Pract., 25, 5.
Steel, J. M., Munro, J. F. and Duncan, L. J. P. (1973). A comparative trial of different regimes of fenfluramine and phentermine in obesity. Practitioner, 211, 232.
Stunkard, A., Rickeis, K. and Hesbacher, P. (1973). Fenfluramine in the treatment of obesity. Lancet, 1, 503.
Vernace, B. J. (1974). Controlled comparative investigations of mazindol, D-amphetamine and placebo. Obesity and Bariatric Med., 3, 124.
Kornhaber, A. (1973). Obesity-depression: clinical evaluation with a new anorexigenic agent. Psychosomatics, 14, 162.
Silverstone, T. (1974), Intermittent treatment with anorectic drugs. Practitioner, 212, 245.
Asher, W. L. (1978). Personal communication.
Enzi, G., Baritussio, A., Machiori, E. and Crepaldi, G. (1976). Short term and long term clinical evaluation of non-amphetamine anorexiant (mazindol) in the treatment of obesity. J. Int. Med. Res., 4, 305.
Hudson, K. D. (1977). The anorectic and hypotensive effect of fenfluramine in obesity. J. Roy. Coll. of Gen. Pract., 27, 497.
Haugen, H. N. (1975). Double blind cross-over study of a new appetite suppressant. Eur. J. Clin. Pharmacol. 8, 71.
Carney, D. E. and Tweddell, E. D. (1975). Double blind evaluation of long acting diethylproprion hydrochloride in obese patients from a general practice. Med. J. Amt., 1, 13.
Miach, P. J., Thomson, W., Doyle, A. E. and Louis, W. J. (1976). Double blind cross-over evaluation of mazindol in the treatment of obese hypertensive patients. Med. J. Aust., 2, 378.
British National Formulary (1976–78) (England: Hazell Watson & Viney Ltd, Aylesbury, Bucks).
Lasagna, L. (1973). Attitudes towards appetite suppressants. J. Am. Med. Assoc, 225, 44.
Smith, R. C. F. (1962). The long term control of obesity using sustained release appetite suppressants. Br. J. Clin. Pract., 16, 6.
Craddock, D. (1973). Obesity and its Management (2nd edn). (London and New York: Churchill Livingstone).
Matthews, P. A. (1975). Diethylpropion in the treatment of obese patients seen in general practice. Curr. Ther. Res., 17, 340.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1979 MTP Press Limited
About this chapter
Cite this chapter
Munro, J.F. (1979). Clinical use of anti-obsesity agents. In: Munro, J.F. (eds) The Treatment of Obesity. Current Status of Modern Therapy, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-1132-2_4
Download citation
DOI: https://doi.org/10.1007/978-94-015-1132-2_4
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-015-1134-6
Online ISBN: 978-94-015-1132-2
eBook Packages: Springer Book Archive